Correction: Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer
- PMID: 32769164
- PMCID: PMC8966981
- DOI: 10.1136/ijgc-2019-001012corr2
Correction: Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer
Erratum for
-
Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer.Int J Gynecol Cancer. 2020 May;30(5):701-704. doi: 10.1136/ijgc-2019-001012. Epub 2019 Dec 22. Int J Gynecol Cancer. 2020. PMID: 31871115 Free PMC article.
References
-
- Mayadev J, Zamarin D, Deng W, et al. Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer International Journal of Gynecologic Cancer Published Online First: 22 December 2019. doi: 10.1136/ijgc-2019-001012 - DOI - PMC - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials